@Revert_EU

Revert project

www.revert-project.eu

info@revert-project.eu

revert
REVERT
taRgeted thErapy for adVanced cororEctal canceR paTients

REVERT

taRgeted thErapy for adVanced cororEctal canceR paTients

revert

The main objective of REVERT is to develop an improved and innovative model of combinatorial therapy – based on personalised medicine – that identifies the most efficient and cost-effective therapeutic intervention for patients with unresectable metastatic colorectal cancer (mCRC).

The specific objectives are:

🟡 **ONE**

To build the **REVERT-DataBase (RDB)** to re-analyse and characterise the pathophysiology of mCRC and to investigate the causes of positive or negative responses to treatments based on established therapeutic interventions in patients with unresectable mCRC.

🟡 **TWO**

To build a sophisticated **AI-based computational framework** to predict patient responses to combinatorial therapies for mCRC care, based on the analysis of new, potential prognostic biomarkers as molecular predictors of therapeutic response or disease outcome

🟡 **THREE**

To v**alidate the health, economic and social impact** of the model in preclinical/ clinical studies across Europe

REVERT

taRgeted thErapy for adVanced cororEctal canceR paTients

The **REVERT project** will address the **specific challenge of understanding at system level the pathophysiology of mCRC cancer** in patients responding well or poorly to therapies, in order to **design optimal strategy for mCRC on a case by case** basis, with therapeutic interventions modulated depending on patient's features.

REVERT

taRgeted thErapy for adVanced cororEctal canceR paTients

REVERT

will generate an EU- network among SMEs,

Research Institutions, Clinical Centres and

Biobanks focused on R&D in the field

of AI-Health for the development of

personalised medicine.

PARTNERS

1. SAN RAFFAELE ROMA SRL (San Raffaele)
2. AZIENDA ULSS 4 VENETO ORIENTALE
   (ULSS 4 - ProMIS)
3. MALMO UNIVERSITET (MALMO UNIV)
4. GENXPRO GMBH (GXP)
5. BUNDESANSTALT FUER MATERIALFORSCHUNG UND
   PRUEFUNG (BAM)
6. UMEA UNIVERSITET (UMEA UNIV.)
7. BIOVARIANCE GMBH (BIOV)
8. FUNDACION UNIVERSITARIA SAN ANTONIO (UCAM)
9. INSTITUTUL REGIONAL DE ONCOLOGIE IASI
   (IRO IASSY)
10. SERVICIO MURCIANO DE SALUD (SMS)
    Affiliated partner:
    Foundation for Health Training and Research of Murcia
    Region (FFIS)

11. LUXEMBOURG INSTITUTE OF HEALTH (LIH)
12. CLUSTERUL REGIONAL INOVATIV DE IMAGISTICA
    MOLECULARA SI STRUCTURALA NORD-EST (IMAGO-MOL)
    Affiliated partners:
    SPIRIDON IASI
    SC EUROCLINIC
    UTGAD IASI
    ROMSOFT
13. OLOMEDIA SRL (Olomedia)
14. UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA (UNITOV)
    Affiliated partners:
    Local Health Unit 3 "Serenissima"
    ISPRO
    "Paolo Giaccone" University Hospital of Palermo
    University of Florence

Accordingly, **REVERT** will build up an innovative artificial intelligence (AI)-based decision support system using the experience and the real-world data of several general Hospitals operating in the EU healthcare system ultimately aimed at developing an improved and innovative model of combinatorial therapy - based on a personalised medicine approach - that identifies the most efficient and cost-effective therapeutic intervention for patients with unresectable mCRC.

This goal will be pursued through the building of the **REVERT-DataBase (RDB)** thanks to a large number of standardized biobank samples with related structured data, and clinical databases (including known clinical and biological features as well as new, potential prognostic/predictive biomarkers) from several major clinical European centres.

The **RDB**, in turn, will be used to build a sophisticated computational framework based on AI to evaluate its impact on survival and quality of life in a prospective clinical trial through testing of new treatment sequences of the available and authorised molecular targeted drugs in patients with mCRC.